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The World Health Organization (WHO) officially declared COVID-
19 a pandemic on 11 March 2020,[1] and it has had far-reaching effects 
on both the international and local fronts. At the time of writing 
(10 September 2020) there had been close to 28 million confirmed 
cases worldwide, with the death toll over 900  000.[2] On 23 March, 
the South African (SA) government announced a strict nationwide 
level 5 lockdown. At Tygerberg Hospital (TBH) in Cape Town, as in 
most hospitals globally, many outpatient departments (OPDs) were 
closed as routine patient follow-up visits and elective surgeries were 
postponed. Furthermore, many healthcare workers were redeployed 
to serve in the front line, preventing them from delivering specialised 
care. Several peripheral clinics were closed for short periods at a 
time, possibly to allow decontamination of the facilities following 
confirmation of COVID-19 cases, resulting in patients not being able 
to access their usual care. Some patients may not have attended their 
follow-up visits for fear of contracting the virus.
In SA, both communicable (mainly tuberculosis and human 
immunodeficiency virus (HIV)) and non-communicable diseases 
(NCDs) contribute to the burden of disease. Globally, there have 
been few studies examining the effect of the COVID-19 pandemic on 
routine patient care and follow-up. To our knowledge, there are only 
three such studies in SA,[3-5] and none specifically looking at the effect 
on biochemical laboratory tests.
Objectives
Since the lockdown was introduced in SA, the laboratory staff at the 
National Health Laboratory Service (NHLS) Chemical Pathology 
Laboratory have subjectively observed a decline in the number of 
routine chemistry requests received, as well as in income generated. 
The objective of this study was to examine the effect of the COVID-
19 response on the routine care of patients followed up at OPDs and 
peripheral hospitals that are serviced by the NHLS Chemical Pathology 
Laboratory at TBH. Since clinical and medication information 
was not available, laboratory request volumes were audited over a 
4-month period after the initiation of hard lockdown. Patient follow-
up was examined in four areas: HIV-infected subjects receiving 
antiretroviral therapy (ART), NCDs, malignancy (haematological 
and thyroid), and neonatal care.
Methods
Study design
This descriptive (observational) study was conducted at the NHLS 
Chemical Pathology Laboratory, TBH. TBH is a tertiary teaching 
hospital affiliated to Stellenbosch University and was the dedicated 
COVID-19 referral centre for Western Cape Province during the 
pandemic.[3] As this was a laboratory study and no clinical or 
medication information was available, laboratory results were used 
as a proxy for patient follow-up. Data were extracted from the NHLS 
laboratory information system (LabTrak) from 1 March to 30 June 
for 2017, 2018, 2019 and 2020. We examined the following as they 
related to the general burden of disease and to some extent the 
paediatric population: (i) ART follow-up: all requests received for 
creatinine follow-up from ART clinics; (ii) NCD follow-up: glycated 
haemoglobin (HbA1c) and lipid profile requests from OPDs and 
peripheral clinics, and free thyroxine (fT4) requests from peripheral 
clinics for patients on levothyroxine therapy; (iii) cancer follow-up: 
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thyroid-stimulating hormone (TSH) and free tri-iodothyronine (fT3) 
requests for patients receiving radioactive iodine treatment, and all 
serum and urine protein electrophoresis (SPEP, UPEP) and serum 
free light chain (SFLC) requests from haematology clinics; and (iv) 
neonatal care: neonatal total serum bilirubin requests from midwife 
obstetric units (MOUs) and peripheral clinics.
Ethical considerations
Patient confidentiality was ensured by labelling data with a unique 
laboratory episode number. No patient recruitment was required. 
The only demographic information recorded was the requesting 
facility. Only the principal investigator and co-investigators had 
access to patient sample information. The study was approved by the 
Ethics Committee of Stellenbosch University (ref. no. N20/07/035_
CIVID-19), and the research was conducted according to the ethical 
principles of the Declaration of Helsinki (2013).
Data analysis
Excel (Office 365; Microsoft, USA) was used to analyse data and to 
construct graphs. Results were grouped and tabulated according to 
analyte, and the month, year and site of collection. The number of 
requests per analyte was compared between each year of the study, 
and the percentage difference was calculated. The trend of requests 
for each month of the study in 2020 was evaluated and compared with 
the trend of requests for the same period in 2019.
Results
During the 4-month study period (1 March - 30 June) in 2020, 
there was a clear decrease in the number of requests received for 
all analytes included in the audit, with the exception of SFLC and 
neonatal total bilirubin, when compared with the same period in 
2017, 2018 and 2019 (Table 1).
The biggest impact was seen on lipids, creatinine, HbA1c, TSH and 
fT3. The percentage difference between 1 March - 30 June 2020 and 
1 March - 30 June 2019 was 59% for lipids and 64% for creatinine 
and HbA1c, while for TSH and fT3 it was 80% and 81%, respectively.
Although the number of neonatal total bilirubin requests remained 
unchanged, the number of clinics from which the laboratory received 
these requests decreased (from 27 in 2019 to 16 in 2020).
Unexpectedly, a downward trend in creatinine requests was noted 
in each consecutive year from 2017 to 2019. Lipid profile, TSH, 
fT4 and fT3 requests decreased in 2018 (relative to 2017), with a 
subsequent increase in 2019.
There was a noteworthy decrease in overall analyte testing from 
March to April 2020 (Fig. 1). Fig. 1 shows a significant decrease 
in April – this coincides with initiation of the level 5 lockdown. 
Although an increase in testing was observed during June 2020 in 
line with the easing of lockdown to levels 4 and then 3, the number 
of requests was still lower compared with the number of requests in 
June 2019 (Table 2).
Discussion
The objective of our study was to determine the impact of SA’s 
COVID-19 lockdown strategy on the routine follow-up of patients 
with communicable diseases and NCDs, specifically patients 
receiving ART, patients being treated for diabetes, dyslipidaemia and 
hypothyroidism, and patients with malignancies (haematological 























Fig. 1. Number of test requests per month during March - June 2020. (HbA1c = glycated haemoglobin; SFLC = serum free light chains; SPEP = serum protein 
electrophoresis; TSH = thyroid-stimulating hormone; fT4 = free thyroxine; fT3 = free tri-iodothyronine; UPEP = urine protein electrophoresis.)
Table 1. Number of requests received from 1 March to 30 June for 2017 - 2020
Analyte 2017 2018 2019 2020
Difference, %
2017 and 2018 2018 and 2019 2019 and 2020
Neonatal total bilirubin 649 1 112 1 234 975 71 11 –21
Creatinine 35 113 34 442 10 323 3 713 –2 –70 –64
HbA1c 5 861 6 162 12 120 4 341 5 97 –64
Lipids 1 629 926 1 750 726 –43 89 –59
SFLC 94 158 370 477 68 134 29
SPEP 812 698 354 341 –14 –49 –4
TSH 369 311 341 67 –16 10 –80
fT4 1 981 1 923 3 583 1 651 –3 86 –54
fT3 365 308 334 62 –16 8 –81
UPEP 245 194 117 79 –21 –40 –32
HbA1c = glycated haemoglobin; SFLC = serum free light chains; SPEP = serum protein electrophoresis; TSH = thyroid-stimulating hormone; fT4 = free thyroxine; fT3 = free tri-iodothyronine; 
UPEP = urine protein electrophoresis.
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tests usually requested in the monitoring of these conditions as a proxy of patient 
follow-up.
We noted a distinct decrease in the relevant testing, particularly in April 2020, 
which coincides with initiation of the stage 5 lockdown. This was especially relevant 
for HbA1c (diabetes follow-up), creatinine from ART clinics, and thyroid function 
tests (thyroid malignancy and hypothyroidism follow-up). The follow-up of 
haematological malignancies and neonatal bilirubin was least affected.
During the past 20 years, considerable progress has been made in the fight 
against HIV/AIDS, as the rate of new infections decreased by 39% and the number 
of deaths related to HIV fell by 51%.[6] This progress is threatened by treatment 
interruptions. Creatinine is routinely measured during the follow-up of patients 
receiving ART. We found that there was a 64% reduction in requests received in 
2020 compared with 2019. However, creatinine also decreased between 2018 and 
2019, which could possibly be due to the introduction of point-of-care creatinine 
testing in the clinics. We postulate that the reduction seen between 2019 and 2020 
was due to the lockdown. Madhi et al.[4] also investigated the effects of COVID-19 
on patient follow-up and observed that the average HIV viral load testing conducted 
per week across SA decreased by 22% after lockdown implementation, while CD4+ 
count testing decreased by 33%. A 6-month interruption in ARV treatment has the 
potential to increase the number of HIV-related deaths by 500 000. Five years from 
now, HIV mortality could increase by 40%.[7] Vertical transmission, from mother 
to child, will also potentially double.
A study by Siedner et al.[5] studied the effect of lockdown on primary healthcare 
clinic visits in the northern part of KwaZulu-Natal Province, comparing the 
number of visits prior to and during lockdown. They reported a 20% increase in 
visits to ART clinics just before the implementation of lockdown, and postulated 
that this may have been an attempt to collect antiretrovirals in anticipation of an 
interruption in services. The Western Cape Department of Health is in the process 
of developing a model whereby ART medication is directly delivered to patients’ 
homes. If blood samples are needed, a phlebotomist will be deployed.[8]
Annually, NCDs are responsible for 41 million deaths globally.[9] The pandemic 
has led to significant disruptions in the routine care of NCDs, with many follow-up 
visits postponed in an attempt to lessen the burden on hospitals. Healthcare workers 
from various departments have been redeployed to assist in the management of 
COVID-19 cases.[10] We found that the number of HbA1c requests, serving as a 
marker for the follow-up of diabetic patients, was 64% lower than in 2019. We 
found an impressive increase in the number of HbA1c requests between 2018 and 
2019, and postulate that this was due to the introduction of routine HbA1c testing 
as a screening test for diabetes and test redistribution, with more requests being 
sent to our laboratory from the catchment area. Similarly, the number of lipid 
profile requests, a marker of dyslipidaemia follow-up, decreased by 59%.
A survey completed by 47 countries confirmed a change in the management of 
patients with NCDs. Thirty-eight percent of respondents reported that diabetic 
patients were most affected.[11] A second survey, by the WHO,[9] concluded that 
the impact of COVID-19 on NCDs is a global phenomenon; however, low-income 
countries are more affected. This survey reported that 49% of services for diabetes 
and related complications have been disrupted.[9]
SPEP, UPEP and SFLC are used in the monitoring of patients with monoclonal 
gammopathies. We noticed a sharp decrease in SPEP requests between 2018 and 
2019, which coincides with the introduction of SPEP testing in Eastern Cape 
Province at this time and therefore a decrease in requests received at our laboratory. 
In comparison with 2019, our study showed a significant decrease in UPEP requests 
in 2020 (32%), a marginal decrease in SPEP requests (4%) and an increase in 
SFLC requests (30%) from haematology clinics, suggesting that follow-up of these 
patients continued, even during the lockdown. Lack of patient access to devices 
with telecommunication capabilities could explain their ongoing clinic follow-up. 
Since 2019, SFLC analysis became part of the multiple myeloma monitoring profile 
at a neighbouring tertiary hospital, Groote Schuur Hospital, and the samples are 
referred to TBH. This may explain the increase in request volume compared with 
previous years.
TSH and fT3 are routinely requested by the radioactive iodine ablation clinic 
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requests decreased dramatically from 2019 to 2020 (80% and 81%, 
respectively). A small study in Jordan[12] evaluating the impact 
of COVID-19 on the treatment of thyroid cancer showed that 
surgical procedures were unaffected; however, adjunct treatment 
with radioactive iodine was altered. The change in treatment strategy 
led to additional financial costs to patients, and increased anxiety in 
some.[12] The decrease in fT4 requests from peripheral clinics between 
2019 and 2020 may be indicative of the suspension of routine follow-
up of patients on levothyroxine due to the lockdown. The increase in 
fT4 that we noted between 2018 and 2019 is possibly due to referral of 
specimens from the peripheral clinics to our laboratory with a change 
in the catchment area.
The COVID-19 pandemic has affected the management of cancer 
patients in various ways. Many screening programmes have been 
halted, which is likely to lead to delayed diagnoses and adverse 
patient outcomes.[13] A 72% reduction has been reported in the 
number of suspected cancer patients referred for further investigation 
by primary care physicians in Scotland, compared with previous 
weekly averages in the month of April.[14]
The effect of COVID-19 on neonatal care has not been well 
described. Neonatal total bilirubin was included as part of our study 
to evaluate the effect of the pandemic on the monitoring of neonatal 
jaundice. We illustrated that the number of requests in 2020 was 
consistent with requests in previous years; however, these requests 
were received from fewer clinics compared with 2019. The decreased 
number of clinics could be due to downscaling of obstetric services or 
closure of clinics during deep-cleaning procedures. Inevitably, patients 
who are normally served by the affected MOUs and clinics would have 
been redirected to other healthcare facilities, placing additional strain 
on an already overburdened system.
A survey in Oregon, USA, investigating changes in immunisation 
practices due to COVID-19, reported a 50% rate of cancellation or 
rescheduling of immunisations.[15] One of the concerns raised by 
clinics participating in the survey was the possible loss of follow-up 
of children who had missed immunisations. The decline in routine 
childhood vaccinations increases the risk of communicable diseases,[16] 
such as measles, pertussis and rotavirus-associated gastroenteritis.[17]
As has been reported by others, we found that much of the focus 
on healthcare seems to have been directed to COVID-19. If access 
to certain types of care is reduced, people’s health is likely to suffer. 
Indeed, a sharp increase in the number of natural deaths has been 
observed since the beginning of May across SA, the Western Cape 
and the Cape Town metro.[18] A possible explanation for this increase 
could be that patients are refraining from seeking medical care. The 
Centers for Disease Control and Prevention in the USA reported a 
20% decrease in emergency room visits for myocardial infarctions 
and CVAs compared with pre-pandemic figures.[19] A 10% reduction 
in visits for diabetic-related complaints was observed.
Study limitations
Although our study had several strengths, such as using a large 
number of tests reflecting both NCDs and communicable diseases 
spread over the past 3 years, it also had several limitations. The study 
looked at laboratory test requests as a proxy for routine patient care, 
and no clinical information was used to assess patient follow-up. We 
only investigated the impact on patient care by looking at requests 
received at a tertiary hospital laboratory in the public sector, and 
are therefore unable to report on the impact in private practice and 
at smaller laboratories. Clinical information is rarely provided on 
laboratory request forms, so it is possible that not all fT4 and HbA1c 
requests were for patients on levothyroxine or for diabetic follow-up, 
respectively. As this study only included tests performed at a chemical 
pathology laboratory, the impact on prominent communicable 
diseases such as tuberculosis and malaria could not be determined. 
It is likely that non-COVID-19 patient care has been affected to an 
equal extent in other parts of SA and Africa in general, but we are 
unable to confirm this. Another possible limitation is that we did not 
determine whether the reductions noted were due to the introduction 
of point-of-care testing by our clients. This is unlikely, however, as it 
would have taken time to introduce, and the instrument would have 
needed to be verified using laboratory results as a gold standard.
Conclusions
This study focused on the short-term healthcare consequences of the 
SA response to the COVID-19 pandemic. The long-lasting effects on 
the management of both communicable diseases and NCDs have yet 
to be established. In the immediate aftermath, the healthcare system 
in SA will be overwhelmed as it tries to relieve the backlog caused by 
suspended routine services, and in the long term it may be affected 
as it attempts to manage complications caused by delayed diagnoses.
The lack of follow-up during lockdown could result in the delayed 
detection of abnormal HbA1c and lipids, increasing risk for CVD. 
The suspension of clinical trials in cancer research has resulted in 
fewer possible treatment options for individuals who might otherwise 
have been included in these trials, and will also lead to delays in 
newer therapies becoming available to the public.
Telemedicine has been widely proposed as an alternative to 
physical interaction between patients and healthcare workers during 
these unprecedented times. While this novel form of patient care 
could be a welcome solution in developed countries, it is probably not 
feasible in much of Africa and other low-income countries.
We have been successful in limiting the potentially devastating 
effects of one pandemic. The next challenge will be to manage the 
possible surge of NCD complications, and a well-co-ordinated 
response will be just as important if we are to emerge victorious. 
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